The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults

Sinocelltech

Status and phase: Completed; Phase 2; Phase 1

Conditions: COVID-19

Treatments: Other: Saline; Biological: SCTV01C; Other: Adjuvant

Study type: Interventional

Funder types: Industry

Identifiers

NCT05148091

SCTV01C-02-1

Details and patient eligibility

About

SCTV01C-02-1 is a randomized, double-blind, placebo controlled Phase Ⅰ/Ⅱ clinical trial of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant bivalent trimeric S protein vaccine manufactured by Sinocelltech, Ltd. The purpose of this study is to evaluate the safety , tolerability and immunogenicity of the experimental vaccine in healthy adults aged ≥ 18 Years previously unvaccinated.

Full description

This study is a randomized, double-blind, multi-center, placebo-controlled phase Ⅰ/Ⅱ clinical trial in adults aged ≥ 18 years previously unvaccinated. The purpose of this study is to evaluate the safety , tolerability and immunogenicity of the experimental SARS-CoV-2 protein vaccine (SCTV01C). The experimental vaccine and adjuvant (one placebo) were both manufactured by Sinocelltech, Ltd., while the saline (the other placebo) was commercially purchased. A total of 752 participants will be enrolled, with 112 at phase Ⅰ, and 640 at phase Ⅱ. There will be two dosage levels (20μg and 40μg), and two age groups (18~59 years old and ≥ 60 years old ) at both Phase Ⅰ and Phase Ⅱ. All of participants will be assigned to receive two doses of experimental vaccine(20μg or 40μg) or placebo (Adjuvant or Saline) on the schedule of Day 0 and Day 28.

Enrollment: 478 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Aged ≥18 years old when signing ICF;
• No other anti-SARS-COV-2 vaccines (approved for marketing or registered study) have been previously administered;
• Participants can sign written ICF and voluntarily participate in the study, and can fully understand the study procedure and the risk of participating in the study,
• Participants should have the ability to read, understand and fill the vaccination record card (VRC);
• Only for participants in Phase I : Those who are clinically judged to be healthy, the results of physical examination, vital signs and laboratory tests during the screening phase are normal;
• Only for participants in Phase II: Healthy participants or participants with stable underlying diseases;
• Fertile men and women of childbearing age voluntarily agree to take effective contraceptive measures from signing ICF to 6 months after full vaccination; the pregnancy test results of women of childbearing age are negative on screening.

Exclusion criteria

• Presence of fever within 72 h before vaccination (axillary temperature ≥ 37.3℃), or active tuberculosis, or in the acute phase of other diseases;
• A history of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), or other coronavirus infections or illness or relevant
• A history of allergic reactions to any vaccine or drug, such as allergy, urticaria, severe skin eczema, dyspnea, laryngeal edema, and angioneurotic edema;
• A medical or family history of seizure, epilepsy, encephalopathy and psychosis;
• Immunocompromised patients suffering or suffered from immunodeficiency diseases, important organ diseases, or immune diseases, etc.;
• Long-term use of immunosuppressive or immunomodulatory drugs for 14 or more days within 6 months prior to study enrollment, or planned use of immunosuppressive or immunomodulatory drugs within 2 years after study enrollment. The use of inhaled and topical corticosteroid is permitted;
• For Phase I participants only: Previously or currently suffering from clinically significant cardiovascular diseases (except for the hypertension that can be controlled with drugs), or clinically significant disorders related to respiratory system, liver and kidney (except for light fatty liver), gastrointestinal system (except for chronic gastritis), endocrine system, blood and lymphatic system, metabolic and skeletal systems, or malignancies (except for skin basal cell carcinoma and carcinoma in-situ of cervix), that may affect the study assessment, or cause risks during the study vaccination, or interfere with the data interpretation as determined by the investigator; For Phase II participants only: Presence of severe or uncontrollable cardiovascular diseases, or severe or uncontrollable disorders related to endocrine system, blood and lymphatic system, liver and kidney, respiratory system, metabolic and skeletal systems, or malignancies (except for skin basal cell carcinoma and carcinoma in-situ of cervix);
• Contraindications for intramuscular injection or intravenous blood sampling, including thrombocytopenia and other blood coagulation disorders;
• Participants who received any immunoglobulin or blood products in the previous 3 months, or plan to receive similar products during the study;
• Participants who received other intervention investigational drugs within 1 month before the vaccination (Except for the participants in the saline control group participating in the clinical study of COVID-19 vaccine);
• Participants vaccinated with influenza vaccine within 14 days, or with other type of vaccines within 28 days before the vaccination;
• Those who donated blood or had blood loss (≥450 mL) within 3 months before the first dose vaccination or plan to donate blood during the study period;
• Those who are pregnant or breast-feeding;
• Those who plan to donate ovum or sperms during the study period;
• Those who cannot follow the study procedures, or cannot cooperate to complete the study due to planned relocation or long-term outing;
• Those unsuitable for participating in the clinical study as determined by the investigator because of other abnormalities that are likely to confuse the study results, or non-conformance with the maximal benefits of the participants;
• For Phase I participants only: those who are tested positive for hepatitis B virus (HBV), hepatitis C virus (HCV), syphilis or HIV in terms of etiology or serology; For Phase II participants only: those who are tested positive for HIV in terms of etiology or serology.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

478 participants in 12 patient groups, including a placebo group

18~59 yrs. low dosage (20 μg) - SCTV01C VACCINE

Experimental group

Description:

20 participants in Phase I and 120 participants in Phase II at the age of 18\~59 years old will receive two doses of low dosage (20 μg/0.5mL) SCTV01C VACCINE on Day 0 and Day 28

Treatment:

Biological: SCTV01C

18~59 yrs. low dosage (20 μg) - Adjuvant (SCT-VA02B )

Placebo Comparator group

Description:

4 participants in Phase I and 20 participants in Phase II at the age of 18\~59 years old will receive two doses of study adjuvant (SCT-VA02B ,0.5mL) on Day 0 and Day 28

Treatment:

Other: Adjuvant

18~59 yrs. low dosage (20 μg) - Saline

Placebo Comparator group

Description:

4 participants in Phase I and 20 participants in Phase II at the age of 18\~59 years old will receive two doses of saline (0.5mL) on Day 0 and Day 28

Treatment:

Other: Saline

≥60 yrs. low dosage (20 μg) - SCTV01C VACCINE

Experimental group

Description:

20 participants in Phase I and 120 participants in Phase II at the age of ≥60 years old will receive two doses of low dosage (20 μg/0.5mL) SCTV01C VACCINE on Day 0 and Day 28

Treatment:

Biological: SCTV01C

≥60 yrs. low dosage (20 μg) - Adjuvant (SCT-VA02B )

Placebo Comparator group

Description:

4 participants in Phase I and 20 participants in Phase II at the age of ≥60 years old will receive two doses of study adjuvant (SCT-VA02B, 0.5mL) on Day 0 and Day 28

Treatment:

Other: Adjuvant

≥60 yrs. low dosage (20 μg) - Saline

Placebo Comparator group

Description:

4 participants in Phase I and 20 participants in Phase II at the age of ≥60 years old will receive two doses of saline (0.5mL) on Day 0 and Day 28

Treatment:

Other: Saline

18~59 yrs. high dosage (40 μg) - SCTV01C VACCINE

Experimental group

Description:

20 participants in Phase I and 120 participants in Phase II at the age of 18\~59 years old will receive two doses of high dosage (40 μg/0.5mL) SCTV01C VACCINE on Day 0 and Day 28

Treatment:

Biological: SCTV01C

18~59 yrs. high dosage (40 μg) - Adjuvant (SCT-VA02B )

Placebo Comparator group

Description:

4 participants in Phase I and 20 participants in Phase II at the age of 18\~59 years old will receive two doses of study adjuvant (SCT-VA02B, 0.5mL) on Day 0 and Day 28

Treatment:

Other: Adjuvant

18~59 yrs. high dosage (40 μg) - Saline

Placebo Comparator group

Description:

4 participants in Phase I and 20 participants in Phase II at the age of 18\~59 years old will receive two doses of saline (0.5mL) on Day 0 and Day 28

Treatment:

Other: Saline

≥60 yrs. high dosage (40 μg) - SCTV01C VACCINE

Experimental group

Description:

20 participants in Phase I and 120 participants in Phase II at the age of ≥60 years old will receive two doses of high dosage (40 μg/0.5mL) SCTV01C VACCINE on Day 0 and Day 28

Treatment:

Biological: SCTV01C

≥60 yrs. high dosage (40 μg) - Adjuvant (SCT-VA02B )

Placebo Comparator group

Description:

4 participants in Phase I and 20 participants in Phase II at the age of ≥60 years old will receive two doses of study adjuvant (SCT-VA02B, 0.5mL) on Day 0 and Day 28

Treatment:

Other: Adjuvant

≥60 yrs. high dosage (40 μg) - Saline

Placebo Comparator group

Description:

4 participants in Phase I and 20 participants in Phase II at the age of ≥60 years old will receive two doses of saline (0.5mL) on Day 0 and Day 28

Treatment:

Other: Saline